Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma

Changed from: Inclusion Criteria: * Confirmed diagnosis of multiple myeloma with either Durie-Salmon stage I, II, or III or ISS stage I, II or III, less than 12 months since initiation of systemic therapy * ≥8x106 CD34+cells/kg available in cryopreservation in aliquots appropriate for tandem transplants * Age: 18-75 years at time of transplantation * KPS 70-100% * Recovery from complications of prior therapies * Gender: There is no gender restriction Exclusion Criteria: * Diagnosis other than multiple myeloma * Chemotherapy or radiotherapy within 8 days of initiating treatment in this study * Prior autologous or allogeneic transplantation (except as enrolled into this study) * Uncontrolled bacterial, viral, fungal or parasitic infections